>ketamine loses antidepressant effects when opioid receptors are blocked with naltrexone). . That was a small trial and another trial showed opposite results

>ketamine loses antidepressant effects when opioid receptors are blocked with naltrexone). . That was a small trial and another trial showed opposite results such as this one https://pubmed.ncbi.nlm.nih.gov/30624551/ https://pubmed.ncbi.nlm.nih.gov/30624551/ More details here https://www.tandfonline.com/doi/full/10.1080/17460441.2020.1781812 https://www.tandfonline.com/doi/full/10.1080/17460441.2020.1... I believe more research is required for r-ketamine (arketamine) I wonder if it has effects on the opiod system also They also thought that the mtor pathway was necessary but trials with human subjects and rapamycin showed that it potentiated the AD effects in humans . Which is sad to hear because it was the basis to the creation of NV-5138 that's heading towards phase 2 soon . It could very well work because the mtor pathway Is complicit In mood disorders . Also advances towards TMS is very interesting check out stanford's SAINT TMS trial Currently what I'm interested in is vistagen's pipeline of drugs . It works unlike any thing else and also the various FAAH inhibitors